Roche and Freenome struck a multi-year collaboration giving Roche exclusive ex‑US commercialization and kit‑development rights for Freenome’s blood-based cancer screening tests, alongside a $75 million equity investment and milestone/royalty provisions. The agreement also opens Roche sample cohorts and lab tech for Freenome’s development and contemplates Roche sequencing-by-expansion tech in future workflows. Freenome keeps US rights and a central testing pathway, while Roche gains distributed kit capability for global rollouts. The deal signals continued consolidation and partner-led scale-up in the nascent multi‑cancer early detection market.